FDA Approves Journavx, First-in-Class Non-Opioid Pain Medication for Acute Pain

The FDA has approved Journavx (suzetrigine), a first-in-class non-opioid pain medication for adults experiencing moderate to severe acute pain. Developed by Vertex Pharmaceuticals, Journavx targets sodium channels in the peripheral nervous system to reduce pain before it reaches the brain. This milestone aligns with the FDA’s efforts to expand non-opioid pain management options as part of its Overdose Prevention Framework. Clinical trials demonstrated its effectiveness following surgeries like abdominoplasty and bunionectomy. Journavx, which received Breakthrough Therapy and Priority Review designations, offers a new alternative to opioids. More details: FDA Announcement.